A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Please contact Rodrigi@sutterhealth.org and firstname.lastname@example.org about Study Metastatic (Idera Melanoma)Location: Sacramento/Valley Area)
View study details on ClinicalTrials.gov
Idera Pharmaceuticals, Inc.
June 06, 2018